Lisinopril
Treatment for Ischemic Heart Disease
Typical Dosage: 5-40mg daily
Effectiveness
80%
Safety Score
70%
Clinical Trials
11
Participants
150K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
5-40mg daily
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
30(Treat 30 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20
Monitoring:$100
Side Effect Mgmt:$20
Total Annual:$140
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$187
Comparison vs No treatment
Cost Difference
+$140/year
More expensive
QALY Difference
+1.20 QALYs
Better outcomes
Dominance
No dominance
Lisinopril Outcomes
for Ischemic Heart Disease
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Common Side Effects
Cough
+15%
Hypotension
+5%
Hyperkalemia
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
8 completed trials for Lisinopril in Ischemic Heart Disease
Genetics of Hypertension Associated Treatments (GenHAT)
NCT00006294COMPLETED
37.9K participants
OBSERVATIONAL
Lexington, United States
Started: Sep 1, 1999
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
NCT03417388COMPLETEDPHASE4
2.48K participants
INTERVENTIONAL
Mobile, United States +80 more
Started: Feb 9, 2018
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
NCT00000542COMPLETEDPHASE3
INTERVENTIONAL
Started: Aug 1, 1993
Reducing Total Cardiovascular Risk in an Urban Community
NCT00241904COMPLETEDPHASE4
525 participants
INTERVENTIONAL
Baltimore, United States
Started: May 1, 2006
Microvascular Disease Exercise Trial
NCT02045459COMPLETEDNA
79 participants
INTERVENTIONAL
Charlottesville, United States +1 more
Started: May 1, 2014
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
NCT00563901COMPLETED
37.9K participants
OBSERVATIONAL
Minneapolis, United States +1 more
Started: Sep 1, 2000
Physical and Chemical Study of Atherosclerosis Mechanisms
NCT01700075COMPLETEDPHASE4
97 participants
INTERVENTIONAL
Almaty, Kazakhstan
Started: Jan 1, 2009
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
NCT00000620COMPLETEDPHASE3
10.3K participants
INTERVENTIONAL
Minneapolis, United States +6 more
Started: Sep 1, 1999